

# Computational Estimation of the Effects of the S210R Mutation on the Structure and Enzymatic-Activity of CYP2B6 Using Molecular Dynamics Simulation

Tomoki Nakayoshi<sup>1,2,3</sup>, Ayato Mizuno<sup>1</sup>, Shuki Yamazaki<sup>4</sup>, Eiji Hishinuma<sup>5</sup>, Masahiro Hiratsuka<sup>4,5</sup>, Koichi Kato<sup>1,6</sup>, Akifumi Oda<sup>1</sup>

1. Faculty of Pharmacy, Meijo University
2. Institute for Advanced Research, Nagoya University
3. Graduate School of Information Sciences, Hiroshima City University
4. Graduate School of Pharmaceutical Sciences, Tohoku University
5. Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University
6. Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences




## Introduction

### Cytochrome P450 2B6 (CYP2B6)

- CYP2B6 is a type of phase I drug-metabolizing enzyme with a heme as an active center.
- CYP2B6 is reported to catalyze metabolic reactions for approximately 7% of clinical drugs, e.g. efavirenz (EFZ) anti-human immunodeficiency virus drug.

#### CYP2B6-catalyzed metabolic reaction of EFZ




### Enzymatic activity of CYP2B6 allelic variants

- **Genetic polymorphisms of CYP2B6 can affect their enzymatic functions**, directly contributing to individual difference in drug efficacy and toxicity.
- We recently analyzed the enzymatic activities of rare allelic variants detected in Japanese [1], and several variants exhibited remarkable reductions in enzymatic activities.
  - ✓ **The enzymatic activity was not detected in the S210R mutants.**


## Results and Discussion

### Simulation stability


RMSDs for C $\alpha$  atoms of CYP2B6



RMSDs for heavy atoms of EFZ




### Differences in the hydrogen bonds with



- S210R mutation did not affect the relative position of EFZ, but it remarkably reduced the occurrence frequencies of hydrogen bonds between Ser294 and EFZ.

## Aims

- As previously mentioned, our recent study has shown that the enzymatic activities of the S210R mutant is significantly reduced compared to that of the wild-type CYP2B6.
- However, the differences in the structural features between the wild-type CYP2B6 and S210R variants were unclear.




- **Molecular dynamics (MD) simulations were performed to elucidate the cause of reduction in enzymatic activity of S210R variants.**

## Molecular Dynamics Simulations

- Initial structures of CYP2C19 for MD simulations were constructed using crystal structures (PDB ID: 3IBD).
- Force-field parameters
  - Amino acid residues: AMBER ff14SB force field
  - Heme and ligated Cys: Our determined parameters [2]
  - Solvent water molecules: TIP3P
  - EFZ: General Amber Force Field 2
- Generation of NPT ensemble
  - Pressure: 1 bar (Monte Carlo barostat)
  - Temperature: 300 K (Langevin thermostat)
- MD production run; 1.5  $\mu$ s (time step: 2 fs)
  - Snapshots were sampling every 2 ps.
  - The final 100-ns trajectories were analyzed.

### Structural differences near the mutation site



- In the  $\beta$ 4 region in wild type,  $\beta$ -sheet structure formed with a high frequency of 95.1%. In contrast, in the  $\beta$ 4 region in S210R mutant,  $\beta$ -sheet structure did not formed at all.
- Side chain of Arg residue is more bulky than that of Ser, and it is considered to be because side-chain orientation of Ile480 significantly differs between wild type and S210R mutant due to steric hindrance.

## Conclusions

- S210R mutation disrupted  $\beta$ -sheet formation in  $\beta$ 4 region that forms the active site and hydrogen-bond formation between EFZ and Ser294. This can explain why the S210R mutant exhibits significantly lower enzyme activity.

## References

1. S. Yamazaki, E. Hishinuma, Y. Suzuki, A. Ueda, C. Kijogi, T. Nakayoshi, A. Oda, S. Saito, S. Tadaka, K. Kinoshita, M. Maekawa, Y. Sato, M. Kumondai, N. Mano, N. Hirasawa, M. Hiratsuka, *Biochem. Pharmacol.*, 229, 116515 (2024)
2. A. Oda, N. Yamaotsu, S. Hirono, *J. Comput. Chem.*, 26, 818–826 (2005)